Challenges of Systemic Therapy for Patients with EGFR-mutated Lung Cancer After Progression on Targeted Therapy

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination

Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm?

Regulatory News for April 24, 2024

Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt

More Than Ever, Surgeons Must Collaborate to Ensure Patients Receive Appropriate Care

A New Treatment Option for Early-Stage ALK+ NSCLC: Adjuvant Alectinib

European Commission Approves Tislelizumab for Three Indications in Non-Small Cell Lung Cancer

In Case You Missed It: Recent News from IASLC